{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Immune cell depletion is defined as immunosuppression of participants T cells prior to transplant measured by cluster of differentiation 4 (CD4) counts (i.e. cells) \\> 50 cells per ul.Immune T-cell depletion helps to reduce the ability to reject allogeneic cells in participants and is required for engraftment. Engraftment is the body's ability to accept donor cells.","groups":[{"description":"Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and GCSF followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.","id":"OG000","title":"Recipient - Chemotherapy Group"}],"paramType":"NUMBER","populationDescription":"This outcome measure was only pre-specified to be measured in the recipient Arm/Group.","reportingStatus":"POSTED","timeFrame":"105 days","title":"Immune Response","type":"PRIMARY","unitOfMeasure":"Particpants"}